Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Neuroblastoma 2Myelodysplastic Syndromes 2Multiple Myeloma 2Leukemia, Myelomonocytic, Chronic 2Breast Neoplasms 2Anemia, Refractory, with Excess of Blasts 2Wilms Tumor 1Uveal Melanoma 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Oligodendroglioma 1Neoplasms, Germ Cell and Embryonal 1Neoplasm Metastasis 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Extranodal NK-T-Cell 1Leukemia, Myeloid, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Hepatoblastoma 1Gliosarcoma 1Glioma 1Glioblastoma 1GATA2 Deficiency 1Carcinoma, Lobular 1Carcinoma, Ductal, Breast 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 37Magnetic Resonance Spectroscopy 21Radiotherapy 18Specimen Handling 15Radiation 10Lomustine 9Bevacizumab 8pembrolizumab 7fludarabine 5Cyclophosphamide 5Surgical Procedures, Operative 4Nivolumab 4Ipilimumab 4Biopsy 4olaparib 3atezolizumab 3Immunoglobulin G 3Disulfides 3Carboplatin 3veliparib 2trametinib 2rocakinogene sifuplasmid 2ribociclib 2poly ICLC 2pamiparib 2niraparib 2lutetium Lu 177 dotatate 2gallium maltolate 2durvalumab 2dabrafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioblastoma × Vorinostat × 90 days × Clear all
NCT00268385 2026-05-07

Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas

National Cancer Institute (NCI)

Phase 1 Active not recruiting
83 enrolled
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡